TC-5214 + Placebo

Phase 1Completed

1 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Elderly Subjects 65 Years and Older, Healthy or With a Stable Disease and Treatment.

Conditions

Elderly Subjects 65 Years and Older, Healthy or With a Stable Disease and Treatment.

Trial Timeline

Jan 1, 2011 → May 1, 2011

NCT ID

NCT01239771

About TC-5214 + Placebo

TC-5214 + Placebo is a phase 1 stage product being developed by AstraZeneca for Elderly Subjects 65 Years and Older, Healthy or With a Stable Disease and Treatment.. The current trial status is completed. This product is registered under clinical trial identifier NCT01239771. Target conditions include Elderly Subjects 65 Years and Older, Healthy or With a Stable Disease and Treatment..

What happened to similar drugs?

1 of 2 similar drugs in Elderly Subjects 65 Years and Older, Healthy or With a Stable Disease and Treatment. were approved

Approved (1) Terminated (0) Active (1)

✅DonepezilEisaiApproved

🔄EsmirtazapineMerckPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (8)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01392820	Phase 1	Completed	Jul 1, 2011	Oct 1, 2011	Healthy
NCT01239771	Phase 1	Completed	Jan 1, 2011	May 1, 2011	Elderly Subjects 65 Years and Older, Healthy or With a Stable Disease and Treatment.
NCT01197508	Phase 3	Completed	Sep 1, 2010	Jan 1, 2012	Major Depressive Disorder
NCT01180400	Phase 3	Completed	Sep 1, 2010	Sep 1, 2011	Major Depressive Disorder
NCT01175564	Phase 1	Completed	Jul 1, 2010	Sep 1, 2010	Healthy
NCT01152554	Phase 3	Completed	Jun 1, 2010	Feb 1, 2012	Major Depressive Disorder
NCT01157078	Phase 3	Completed	Jun 1, 2010	Nov 1, 2011	Major Depressive Disorder
NCT01153347	Phase 3	Completed	Jun 1, 2010	Jan 1, 2012	Major Depressive Disorder

Competing Products

15 competing products in Elderly Subjects 65 Years and Older, Healthy or With a Stable Disease and Treatment.

See all competitors

Product	Company	Stage	Hype Score
YM150 + Placebo	Astellas Pharma	Phase 1	29
ASP3325 + Placebo	Astellas Pharma	Phase 1	29
E2022 Tape Formulation	Eisai	Phase 1	29
Donepezil	Eisai	Approved	43
AZD3293 + Placebo	AstraZeneca	Phase 1	29
AZD3293 + Placebo	AstraZeneca	Phase 1	29
Esmirtazapine	Merck	Phase 3	40
Pertuzumab + trastuzumab + Pertuzumab + trastuzumab + metronomic chemotherapy	Roche	Phase 2	35
PF-06648671 + Midazolam + Placebo	Pfizer	Phase 1	29
PF-06743649 + Placebo + PF-06743649 + Placebo + PF-06743649 + Placebo + PF-06743649 + Placebo + PF-06743649 + Placebo	Pfizer	Phase 1	21
Vitamin D + Sham Exercise + Vitamin D + Exercise	Pfizer	Phase 1	21
HSK3486 + HSK3486 + HSK3486 + HSK3486	Haisco Pharmaceutical Group	Phase 1	29
Padsevonil	UCB	Phase 1	29
TD-1439 + Placebo	Theravance Biopharma	Phase 1	23
TD-0714 + Placebo	Theravance Biopharma	Phase 1	23